Given the above findings of the potential role of inhibiting PGE-2 production along with PD-1/PD-L1 blockade in enhancing immunity against cancer cells, our study aimed to determine whether there is a synergetic effect when combining ASA with immunotherapy in the treatment of non-small cell lung cancer (NSCLC) patients. This evidence concerns the gene CD274 and cancer.